Adrenergic beta-Antagonists: Clinical Trials

108 trials of Adrenergic beta-Antagonists, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

51 completed, 22 unknown, 15 recruiting, 11 terminated. 40 Phase 4, 25 Not applicable, 12 Phase 3, 11 Phase 2, 6 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 440Completed 18, Unknown 8, Recruiting 4, Enrolling by invitation 3, Not yet recruiting 3, Terminated 3, Withdrawn 1
Not applicable25Completed 10, Recruiting 7, Unknown 4, Terminated 3, Not yet recruiting 1
Phase 312Completed 10, Unknown 2
Phase 211Completed 4, Terminated 3, Unknown 2, Not yet recruiting 1, Recruiting 1
Phase 16Completed 4, Terminated 1, Unknown 1

Follow Adrenergic beta-Antagonists: new trials by email Literature Review of Adrenergic beta-Antagonists trials Research Report on Adrenergic beta-Antagonists

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluating Adherence to Guideline-Directed Medical Therapy in Patients With Advanced Heart Failure
GDMT, Quality of life questionnaire - Heart Failure
RecruitingUniversità Vita-Salute San Raffaele3002026-05-082026-07-06
Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes
Catheter ablation, Medical therapy: Anti-arrhythmic drugs (AAD) and/or beta-adrenergic blocking agents (BB) - Premature Ventricular Complexes, Premature Ventricular Contraction (PVC)
Not applicableRecruitingWestern Sydney Local Health District502026-03-312026-09-24
UPBEAT: Using Polygenic Scores to Guide BB Therapy in HF With Mildly Reduced EF
Beta blocker - Heart Failure, Polygenic Score
Not applicableRecruitingDavid Lanfear102026-03-302026-07-07
The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction
mavacamten, Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol, diltiazem - Hypertrophic Cardiomyopathy (HCM)
Phase 4Enrolling by invitationSecond Affiliated Hospital, Zhejiang University, School of Medicine1322026-03-012026-09-15
Pilot Study of StudyU for N-of-1 Trials in HFrEF Patients (N-of-1 App)
beta blockers, StudyU Application - HFrEF - Heart Failure With Reduced Ejection Fraction, Heart Failure
Phase 4Enrolling by invitationWeill Medical College of Cornell University52026-02-102026-02-19
Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)
Placebo (matching), Beta-blockers - Heart Failure, HFpEF
Phase 4Enrolling by invitationWeill Medical College of Cornell University2402026-02-022026-10-16
Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication
Catheter Ablation for Atrial Fibrillation, Rate Control Medications (beta-blockers, calcium channel blockers, digoxin) - Atrial Fibrillation (AF), Heart Failure With Mildly Reduced Ejection Fraction
Not applicableRecruitingNova Scotia Health Authority842026-01-012026-10-20
Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction
Aspirin, Shexiang Baoxin Pill - Acute Myocardial Infarction (AMI), Percutaneous Coronary Intervention (PCI)
Phase 4Not yet recruitingShanghai Hutchison Pharmaceuticals Limited95882025-09-012025-09-04
Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy
Prostaglandin Analogue -Containing IOP-Lowering Therapy, Beta Blocker, Brillouin Microscopy - Glaucoma
RecruitingUniversity of Maryland, Baltimore602025-09-012026-08-10
Short-Term Effects of Antihypertensive Drugs on Postural Balance and Fall Risk
Beta Blocker, ACE inhibitor, Calcium channel blocker - Hypertension, Fall Risk
Not applicableRecruitingAbant Izzet Baysal University1862025-08-012026-02-12
Sacubitril-valsartan in Patients With Heart Failure.
Sacubitril-valsartan, standard treatment of heart failure - Heart Failure
Not applicableCompletedDamanhour University602025-08-012026-04-21
Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression
Propranolol (Beta-Blocker) and Etodolac (COX-2 Inhibitor), Placebo (Matching for Propranolol & Etodolac) - Ovarian Cancer, Ovarian Cancer Metastatic Recurrent
Phase 2RecruitingTel-Aviv Sourasky Medical Center602025-03-122025-07-11
N-of-1 in ATS and MEPPC
Flecainide, Flecainide + beta-blocker - Andersen Tawil Syndrome, Multifocal Ectopic Purkinje-related Premature Contractions
Phase 2Not yet recruitingAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)102025-03-012025-01-29
Early Identification and Treatment of Rare Cardiomyopathy Cohorts
diuretics, ACEIs/ARBs, beta blockers, positive inotropic drugs, MRAs, SGLT2i, retinoids, Close follow-up, early rehabilitation guidance - Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM)
Not applicableNot yet recruitingRenJi Hospital3002025-02-012025-01-27
Beta-Blockers in Takotsubo Syndrome Study
Beta blocker - Takotsubo Cardiomyopathy, Beta-blockers
Phase 4Not yet recruitingSpanish Society of Cardiology2002024-08-012024-08-26
Impact of Beta Blockers on TAVI (BETA-TAVI)
Beta blocker - Aortic Valve Stenosis
Phase 4RecruitingNational and Kapodistrian University of Athens3482024-06-012026-10-20
Detoxification From the Lipid Tract
electroencephalogram biofeedback, electrical brain stimulation, ultra-low frequency transcranial magnetic stimulation - COVID-19 Vaccine Adverse Reaction
Phase 4CompletedPachankis, Yang I., M.D.12024-02-262024-04-10
A Preliminary Study for INFORMED
Beta blocker - Heart Failure, Heart Failure, Diastolic
Phase 4RecruitingWeill Medical College of Cornell University182024-02-072026-08-21
N-of-1 for Beta-Blockers in Cardiac Amyloidosis
Beta blocker - Cardiac Amyloidosis, Heart Diseases
Phase 4CompletedWeill Medical College of Cornell University142024-01-312026-07-29
Development and Validation of the Prediction Model for Functional Mitral Regurgitation Regression in Heart Failure Patients Taking Guideline-directed Medical Therapy
angiotensin-converting enzyme inhibitors/angiotensin II receptor blocker/angiotensin receptor-neprilysin inhibitor, The development of the prediction model - Mitral Regurgitation, Heart Failure
UnknownSun Yat-Sen Memorial Hospital of Sun Yat-Sen University2702024-01-012024-02-26

Showing 20 of 108. Sign in to see all of them.

Conditions studied

Heart Failure (26)  ·  Heart Diseases (13)  ·  Atrial Fibrillation (11)  ·  Hypertension (10)  ·  Cardiovascular Diseases (9)  ·  Myocardial Infarction (7)  ·  Acute Coronary Syndrome (4)  ·  Coronary Artery Disease (4)  ·  Diabetes Mellitus (4)  ·  Fibrosis (4)  ·  Breast Neoplasms (3)  ·  Cardiomyopathy, Dilated (3)  ·  Heart Failure, Diastolic (3)  ·  Hemangioma (3)  ·  Hypotension (3)

Sponsors

Weill Medical College of Cornell University (6)  ·  University of Sao Paulo (3)  ·  Assiut University (2)  ·  Boehringer Ingelheim (2)  ·  Cedars-Sinai Medical Center (2)  ·  Chongqing Medical University (2)  ·  Govind Ballabh Pant Hospital (2)  ·  Johns Hopkins University (2)  ·  NYU Langone Health (2)  ·  National Heart, Lung, and Blood Institute (NHLBI) (2)  ·  National Institute of Cardiology, Warsaw, Poland (2)  ·  Policlinico Casilino ASL RMB (2)  ·  RenJi Hospital (2)  ·  Spanish Society of Cardiology (2)  ·  Tel-Aviv Sourasky Medical Center (2)

Countries

United States (29)  ·  China (11)  ·  Italy (7)  ·  United Kingdom (6)  ·  Brazil (5)  ·  Canada (5)  ·  Spain (5)  ·  Australia (3)  ·  Egypt (3)  ·  Israel (3)  ·  Sweden (3)  ·  Denmark (2)  ·  Germany (2)  ·  India (2)  ·  Netherlands (2)

Top investigators

Parag Goyal, MD, MSc (4)  ·  Parag Goyal, MD (2)  ·  Shiv K Sarin, MD, DM (2)  ·  Alan Maisel, MD (1)  ·  Alberto Zanchetti (1)  ·  Alp Ozel, PT, PhD (1)  ·  Andrew Ambrosy, MD, MPH (1)  ·  Anna Blecher, Dr. (1)  ·  Anna Maria Scandroglio, MD (1)  ·  Bernard Chaitman, MD (1)  ·  Bertil Lindahl, Prof (1)  ·  Burton Sobel (1)  ·  Carlos Robles-Medranda, M.D. (1)

Results publications

PMID 21145834, PMID 42478107, PMID 17105759, PMID 17543250, PMID 19152871, PMID 19329766, PMID 19407805, PMID 20551457, PMID 21051458, PMID 21444887, PMID 21473976, PMID 21617110, PMID 21742107, PMID 21768545, PMID 21835316, PMID 21884956, PMID 21911782, PMID 21953407, PMID 22025606, PMID 22032709, PMID 22493073, PMID 22496082, PMID 23008442, PMID 23071495, PMID 23141853, PMID 23327629, PMID 23410541, PMID 23434314, PMID 23500245, PMID 23500281, PMID 23580745, PMID 23735723, PMID 23757426, PMID 23857320, PMID 23910429, PMID 24159564, PMID 24178969, PMID 24297771, PMID 24727262, PMID 24906863, PMID 24931393, PMID 24979303, PMID 25193873, PMID 25281275, PMID 25480782, PMID 26267622, PMID 26271057, PMID 26399404, PMID 26764413, PMID 26853953

NIH funding

K76AG064428 (2), 2009 (1), K76AG088428 (1), R01AG091005 (1), R01HL082638 (1), R01HL126892 (1), R03HL138068 (1), R21CA291683 (1), R21EY035483 (1), R24AG064025 (1), U01HL061744 (1), U01HL061746 (1), U01HL061748 (1), U01HL062509 (1), U01HL063804 (1)